EA202190522A1 - Стабилизированные тримеры гликопротеина филовируса - Google Patents

Стабилизированные тримеры гликопротеина филовируса

Info

Publication number
EA202190522A1
EA202190522A1 EA202190522A EA202190522A EA202190522A1 EA 202190522 A1 EA202190522 A1 EA 202190522A1 EA 202190522 A EA202190522 A EA 202190522A EA 202190522 A EA202190522 A EA 202190522A EA 202190522 A1 EA202190522 A1 EA 202190522A1
Authority
EA
Eurasian Patent Office
Prior art keywords
filovirus
glycoprotein
glycoproteins
amino acid
nucleic acid
Prior art date
Application number
EA202190522A
Other languages
English (en)
Inventor
Йоханнес Петрус Мария Лангедейк
Люси Рюттен
Свен Блокланд
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA202190522A1 publication Critical patent/EA202190522A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14251—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к мутациям гликопротеина филовируса, которые стабилизируют тримерную форму гликопротеина. Гликопротеины филовируса имеют определенные аминокислотные замены в указанных положениях последовательности гликопротеина. Гликопротеины филовируса, описанные в настоящем изобретении, характеризуются увеличенной процентной долей образования тримера и/или увеличенным выходом тримера по сравнению с гликопротеином филовируса, который не содержит одной или более из указанных аминокислотных замен. Также изобретение относится к молекулам нуклеиновой кислоты и векторам, кодирующим гликопротеины филовируса, а также композициям, содержащим гликопротеины филовируса, кодирующую их нуклеиновую кислоту и векторы на ее основе.
EA202190522A 2018-08-13 2019-08-13 Стабилизированные тримеры гликопротеина филовируса EA202190522A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18188675 2018-08-13
PCT/EP2019/071732 WO2020035497A1 (en) 2018-08-13 2019-08-13 Stabilized filovirus glycoprotein trimers

Publications (1)

Publication Number Publication Date
EA202190522A1 true EA202190522A1 (ru) 2021-05-25

Family

ID=63452359

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190522A EA202190522A1 (ru) 2018-08-13 2019-08-13 Стабилизированные тримеры гликопротеина филовируса

Country Status (9)

Country Link
US (1) US11603390B2 (ru)
EP (1) EP3836961A1 (ru)
JP (1) JP2021533772A (ru)
CN (1) CN112823021A (ru)
AU (1) AU2019323115A1 (ru)
BR (1) BR112021001460A2 (ru)
CA (1) CA3107083A1 (ru)
EA (1) EA202190522A1 (ru)
WO (1) WO2020035497A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021001460A2 (pt) 2018-08-13 2021-04-27 Janssen Vaccines & Prevention B.V. trímeros de glicoproteína de filovírus estabilizados

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
CN102711794B (zh) 2010-01-04 2015-11-25 Kj生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
WO2012154203A2 (en) * 2010-10-28 2012-11-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Filovirus fusion proteins and their uses
CA3200425A1 (en) 2012-11-16 2014-05-22 Peter ABBINK Recombinant adenoviruses and use thereof
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EP3344288A1 (en) 2015-09-02 2018-07-11 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
WO2017172622A1 (en) * 2016-03-28 2017-10-05 Integrated Biotherapeutics, Inc. Pan filovirus vaccine compositions and methods of making
CN106868025B (zh) * 2017-03-13 2020-01-21 中国人民解放军军事医学科学院生物工程研究所 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法
BR112021001460A2 (pt) 2018-08-13 2021-04-27 Janssen Vaccines & Prevention B.V. trímeros de glicoproteína de filovírus estabilizados

Also Published As

Publication number Publication date
AU2019323115A1 (en) 2021-01-28
WO2020035497A1 (en) 2020-02-20
BR112021001460A2 (pt) 2021-04-27
EP3836961A1 (en) 2021-06-23
US20210292371A1 (en) 2021-09-23
US11603390B2 (en) 2023-03-14
JP2021533772A (ja) 2021-12-09
CA3107083A1 (en) 2020-02-20
CN112823021A (zh) 2021-05-18

Similar Documents

Publication Publication Date Title
PH12019500280A1 (en) Trimer stabilizing hiv envelope protein mutations
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
EA201891974A1 (ru) Ингибиторы связывания белка wdr5 с белками
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
EA202191622A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
TN2018000159A1 (en) Improved tnf binders.
EA201691589A1 (ru) Стабилизированные основанные на фибронектине каркасные молекулы
EA202092464A1 (ru) Способы получения стабильных композиций на основе белков
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
EA201890198A1 (ru) Новые белки, специфичные в отношении lag-3
EA202192376A1 (ru) Композиции и способы лечения ламинопатий
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
EA202191123A1 (ru) Миниатюризированные дистрофины и их применения
EA202190522A1 (ru) Стабилизированные тримеры гликопротеина филовируса
EA201690826A1 (ru) Рекомбинантные гликопротеиды и их применения
AR107900A1 (es) Un gen de síntesis de tentoxina, un método para producir tentoxina o dihidrotentoxina usando el gen, y un transformante que lo comprende
MX2021003441A (es) Polipeptidos de arginasa1.
EA202090326A1 (ru) Стабилизирующие тример мутации белка оболочки hiv
EA202092694A1 (ru) Системы и способы количественного определения и модификации вязкости белков
AR112339A1 (es) Mutaciones de proteína de envoltura de vih que estabilizan trímeros